IRCT20200623047902N6已完成未知
Bioequivalence study of erlotinib150mg tablet, manufactured by Zistdaru Danesh co. (Erloxha) Versus Tarceva 150 in healthy volunteers
Zistdaru Danesh Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-60 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to erlotinib
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)IRCT20200105046010N46Actero Pharma. Co.24
招募中
不适用
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)Bio equivalence test.IRCT20200105046010N51Abidi Pharmaceutical Company24
已完成
4 期
A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditionsLung CancerNCT04145570Quadras Scientific Solutions24
尚未招募
2 期
To evaluate the efficacy and safety of Erlotinib and Bevacizumab in patients with advanced Non-squamous Non-Small Cell Lung Cancer with brain metastasis who acquired resistance to prior EGFR-TKI treatment harboring EGFR mutation.on-Small-Cell Lung CancerJPRN-UMIN000012515Department of Respiratory Medicine, Kumamoto University Hospital16
进行中（未招募）
不适用
A randomized phase II study of erlotinib compared to single agent chemotherapy-erlotinib combination in pretreated patients with advanced NSCLC (NVALT10 study) - NVALT10patients who failed previous cytotoxic treatment for non-small-cell lung cancer locally advanced and metastatic disease stage IIIB and IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVEUCTR2009-009315-22-NLVALT230